These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 18257772

  • 1. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A, INITIO Trial International Co-ordinating Committee, HAMA study coordination team.
    HIV Med; 2008 Feb; 9(2):101-10. PubMed ID: 18257772
    [Abstract] [Full Text] [Related]

  • 2. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A.
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [Abstract] [Full Text] [Related]

  • 4. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM, Zhang L, Qiu ZF, Xie J, Han Y, Yu W, Li M, Li TS.
    Zhonghua Yi Xue Za Zhi; 2009 Apr 07; 89(13):867-71. PubMed ID: 19671283
    [Abstract] [Full Text] [Related]

  • 5. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.
    Antivir Ther; 2003 Aug 07; 8(4):347-54. PubMed ID: 14518704
    [Abstract] [Full Text] [Related]

  • 6. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P.
    Antivir Ther; 2007 Aug 07; 12(8):1265-71. PubMed ID: 18240866
    [Abstract] [Full Text] [Related]

  • 7. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2007 Aug 07; 12(1):97-105. PubMed ID: 17503753
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S.
    J Infect Dis; 2007 Jun 15; 195(12):1754-61. PubMed ID: 17492590
    [Abstract] [Full Text] [Related]

  • 9. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
    Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, Evison JM, Tarr PE, Schmid P, Perneger T, Hirschel B, Swiss HIV Cohort Study.
    HIV Med; 2008 Mar 15; 9(3):142-50. PubMed ID: 18218001
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A.
    Arterioscler Thromb Vasc Biol; 2003 Apr 01; 23(4):688-94. PubMed ID: 12615670
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
    He G, Andersen O, Haugaard SB, Lihn AS, Pedersen SB, Madsbad S, Richelsen B.
    Eur J Clin Invest; 2005 Sep 01; 35(9):583-90. PubMed ID: 16128865
    [Abstract] [Full Text] [Related]

  • 16. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
    Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.
    J Antimicrob Chemother; 2014 Nov 01; 69(11):3076-84. PubMed ID: 25185137
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults.
    Law M, Puls R, Cheng AK, Cooper DA, Carr A.
    Antivir Ther; 2006 Nov 01; 11(2):179-86. PubMed ID: 16640099
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.